Low-dose IL-2 therapy to maintain Treg homeostasis under the use of calcineurin inhibitor

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K09504
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Hematology
• Research Institution: Okayama University
• Principal Investigator: Tanimoto Mitsune 岡山大学, 医歯薬学総合研究科, 特命教授 (10240805)
• Co-Investigator(Kenkyū-buntansha): 松岡 賢市 岡山大学, 医歯薬学総合研究科, 准教授 (90432640)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 造血幹細胞移植 / 制御性T細胞 / 移植片対宿主病 / 免疫寛容

Outline of Final Research Achievements

We performed allogeneic bone marrow transplantation from B6 donor into B6D2F1 recipient, and thereafter, we administrated immune suppressive agents including CsA,sirolimus and MMF. We found that CsA interfered Treg recovery while sirolimus and MMF promote Treg recovery. Moreover, we observed that low-dose IL-2 therapy and sirolimus syngeneically increased Treg population. Our findings suggest that the impact of LD-IL2 on Treg homeostasis after allogeneic SCT is mostly dependent on the kind of concomitant immune suppressive agents.

Free Research Field

血液学